Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Ramos-Esquivel, Allana; b; * | Rodriguez-Porras, Luisa | Porras, Juanc
Affiliations: [a] Departamento de Oncología Médica., Hospital San Juan de Dios, San José, Costa Rica | [b] Departamento de Farmacologia, Escuela de Medicina, Universidad de Costa Rica, San José, Costa Rica | [c] Departamento de Patología, Hospital San Juan de Dios, San José, Costa Rica
Correspondence: [*] Corresponding author: Allan Ramos-Esquivel. Departamento de Farmacología, Escuela de Medicina, Universidad de Costa Rica, Sede Rodrigo Facio, San José, Costa Rica, P.O. Box: 2082 San José, Tel.: (+506) 88448187; Fax: (+506) 22373930; E-mail: [email protected], [email protected]
Abstract: BACKGROUND:High values of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have been associated with poor prognosis in certain tumors. Nevertheless, few data exist regarding these prognostic variables in breast cancer patients from Hispanic populations. In this study, we aimed to determine the prognostic value of these two estimates and to establish the best cutoff to categorize patients according to their risk. MATERIALS AND METHODS:We retrospectively reviewed 172 consecutive breast cancer patients treated in our center. Pre-treatment NLR and PLR, as well as clinical variables were collected from medical records. Univariate and multivariate Cox regression analyses were performed to assess the relationship between NLR, PLR, overall survival (OS) and disease free survival (DFS), adjusted for potential confounders. The best cut-off point was determined based on the maximization of the Log-rank test statistic. RESULTS:Median follow-up time was 71.3 months. The optimal cut-off for NLR and PLR was 3 and 250, respectively. In univariate analysis, a NLR 3 was associated with poor DFS (Hazard Ratio (HR): 3.92; 95% Confidence Interval (CI): 1.98–7.77; p < 0.001) and reduced OS (HR: 4.20; 95% CI: 2.10–8.38; p < 0.001). Similarly, a PLR 250 was associated with worse DFS (HR: 5.01; 95% CI: 2.33–11.1; p < 0.001) and poorer OS (HR: 5.35; 95% CI: 2.43–11.76; p < 0.001). However, after adjustment for potential confounders, only the PLR was independently associated with worse outcomes. CONCLUSIONS:A NLR greater than 3 and a PLR greater than 250 were associated with worse OS and DFS in Hispanic patients with breast cancer.
Keywords: Breast cancer, lymphocyte, neutrophil, platelet, prognosis
DOI: 10.3233/BD-160251
Journal: Breast Disease, vol. 37, no. 1, pp. 1-6, 2017
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]